JavaScript is disabled. Please enable to continue!

Mobile search icon
Newsletters >> Spring 2022 >> Transition from R&D Cell Line Development to GMP Bank Manufacture

Transition your Therapeutic Program from R&D Cell Line Development to GMP Bank Manufacture in Preparation for Clinical Trials

Sidebar Image

Live Webinar

Wednesday, June 22, 2022 |11am EDT | 8am PDT | 5pm CET

Stem Cell CultureDemand is growing for mammalian cell banking in support of the monoclonal antibody therapeutic and cell and gene therapy fields. Proper cell line development followed by GMP banking is required in order to introduce your therapeutic product candidate into clinical trials. In addition to protein/viral production levels and molecule structural
attributes, regulatory considerations are needed during final clone selection prior to transitioning to GMP banking.

During this webinar, our experts will focus on mammalian cell line development and GMP banking requirements to transition your research from an R&D environment to the GMP regulated manufacturing world to take your molecule into the clinic. Some of the topics that will be discussed during this webinar include:

  • Cell line development considerations for CHO and HEK-293/Sf9
  • Cell line selection and clonality
  • GMP documentation and GMP cell bank production
  • Considerations for characterization and release testing of production cells banks for clinical use

Click here to register